630 results on '"Punyadeera, Chamindie"'
Search Results
152. Authors′ reply
- Author
-
Punyadeera Chamindie, Schneider Marion, Schaffer Dave, Hsu Hsin-Yun, Joos Thomas, Kriebel Fabian, Weiss Manfred, and Verhaegh Wim
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Published
- 2010
153. A collective route to head and neck cancer metastasis
- Author
-
Kulasinghe, Arutha, Schmidt, Henri, Perry, Chris, Whitfield, Bernard, Kenny, Lizbeth, Nelson, Colleen, Ebrahimi Warkiani, Majid, Punyadeera, Chamindie, Kulasinghe, Arutha, Schmidt, Henri, Perry, Chris, Whitfield, Bernard, Kenny, Lizbeth, Nelson, Colleen, Ebrahimi Warkiani, Majid, and Punyadeera, Chamindie
- Abstract
Distant metastasis (DM) from head and neck cancers (HNC) portends a poor patient prognosis. Despite its important biological role, little is known about the cells which seed these DM. Circulating tumour cells (CTCs) represent a transient cancer cell population, which circulate in HNC patients’ peripheral blood and seed at distant sites. Capture and analysis of CTCs offers insights into tumour metastasis and can facilitate treatment strategies. Whilst the data on singular CTCs have shown clinical significance, the role of CTC clusters in metastasis remains limited. In this pilot study, we assessed 60 treatment naïve HNC patients for CTCs with disease ranging from early to advanced stages, for CTC clusters utilizing spiral CTC enrichment technology. Single CTCs were isolated in 18/60–30% (Ranging from Stage I-IV), CTC clusters in 15/60–25% (exclusively Stage IV) with 3/15–20% of CTC clusters also containing leukocytes. The presence of CTC clusters associated with the development of distant metastatic disease(P = 0.0313). This study demonstrates that CTC clusters are found in locally advanced patients, and this may be an important prognostic marker. In vivo and in vitro studies are warranted to determine the role of these CTC clusters, in particular, whether leukocyte involvement in CTC clusters has clinical relevance.
- Published
- 2018
154. Development of paper-based analytical devices for minimizing the viscosity effect in human saliva
- Author
-
Noiphung, Julaluk, Nguyen, Michael, Punyadeera, Chamindie, Wan, Yunxia, Laiwattanapaisal, Wanida, Henry, Charles, Noiphung, Julaluk, Nguyen, Michael, Punyadeera, Chamindie, Wan, Yunxia, Laiwattanapaisal, Wanida, and Henry, Charles
- Abstract
Rationale: Saliva as a sample matrix is rapidly gaining interest for disease diagnosis and point-of-care assays because it is easy to collect (non-invasive) and contains many health-related biomarkers. However, saliva poses particular problems relative to more common urine and blood matrices, which includes low analyte concentrations, lack of understanding of biomolecule transportation and inherent viscosity variability in human samples. While several studies have sought to improve assay sensitivity, few have addressed sample viscosity specifically. The goal of this study is to minimize the effect of sample viscosity on paper-based analytical devices (PADs) for the measurement of pH and nitrite in human saliva. Methods: PADs were used to measure salivary pH from 5.0 to 10.0 with a universal indicator consisting of chlorophenol red, phenol red and phenolphthalein. Nitrite determination was performed using the Griess reaction. Artificial saliva with viscosity values between 1.54 and 5.10 mPa∙s was tested on the proposed PAD. To ensure the proposed PADs can be tailored for use in-field analysis, the devices were shipped to Australia and tested with human specimens. Results: Initial experiments showed that viscosity had a significant impact on the calibration curve for nitrite; however, a more consistent curve could be generated when buffer was added after the sample, irrespective of sample viscosity. The linear range for nitrite detection was 0.1 to 2.4 mg/dL using the improved method. The nitrite measurement in artificial saliva also showed a good correlation with the standard spectrophotometry method (p=0.8484, paired sample t-test, n=20). Measured pH values from samples with varying viscosities correlated well with the results from our pH meter. Conclusions: The inherent variation of salivary viscosity that impacts nitrite and pH results can be addressed using a simple washing step on the PAD without the need for complex procedures.
- Published
- 2018
155. A pilot study to investigate the feasibility of transporting saliva samples at room temperature with MAWI Cell Stabilization buffer
- Author
-
Lim, Yen Kai, Punyadeera, Chamindie, Lim, Yen Kai, and Punyadeera, Chamindie
- Abstract
Saliva is considered as the front-line of non-invasive diagnostics as novel biomarkers continue to emerge for an array of systemic diseases. Biomarker development pipeline relies heavily on pre-analytical process such as saliva collection, handling, transport and storage. The aim of this study was to systematically evaluate the applicability of MAWI Cell Stabilization (MCS) buffer to transport and store saliva samples at room temperature for downstream applications. Human and bacterial genomic DNA (gDNA) and total protein in saliva samples with and without MCS buffer were quantified for a week at three time-points at room temperature. Based on our findings, MCS buffer was able to preserve human gDNA and total protein within the testing time-points. While bacterial gDNA was accurately preserved, MCS buffer was unable to halt bacterial growth at room temperature. We have identified a non-alcohol-based, non-lytic buffer that could maintain the integrity of both genomic materials and proteins in saliva samples. MCS buffer offers a method to potentially transport and store saliva samples at room temperature, accelerating the translation of salivary assays in remote/rural and resource limited settings.
- Published
- 2018
156. Salivary exosomes as potential biomarkers in cancer
- Author
-
Nair, Soumya, Tang, Kai, Kenny, Lizbeth, Punyadeera, Chamindie, Nair, Soumya, Tang, Kai, Kenny, Lizbeth, and Punyadeera, Chamindie
- Abstract
Over the past decade, there has been emerging research in the field of extracellular vesicles, especially those originating from endosomes, referred to as ‘exosomes. Exosomes are membrane-bound nanovesicles secreted by most cell types upon fusion of multivesicular bodies (MVBs) to the cell plasma membrane. These vesicles are present in almost all body fluids such as blood, urine, saliva, breast milk, cerebrospinal and peritoneal fluids. Exosomes participate in intercellular communication by transferring the biologically active molecules like proteins, nucleic acids, and lipids to neighboring cells. Exosomes are enriched in the tumour microenvironment and growing evidence demonstrates that exosomes mediate cancer progression and metastasis. Given the important biological role played by these nanovesicles in cancer pathogenesis, these can be used as ideal non-invasive biomarkers in detecting and monitoring tumours as well as therapeutic targets. The scope of the current review is to provide an overview of exosomes with a special focus on salivary exosomes as potential biomarkers in head and neck cancers.
- Published
- 2018
157. The performance of an oral microbiome biomarker panel in predicting oral cavity and oropharyngeal cancers
- Author
-
Lim, Yen Kai, Fukuma, Naoki, Totsika, Makrina, Kenny, Lizbeth, Morrison, Mark, Punyadeera, Chamindie, Lim, Yen Kai, Fukuma, Naoki, Totsika, Makrina, Kenny, Lizbeth, Morrison, Mark, and Punyadeera, Chamindie
- Abstract
The oral microbiome can play a role in the instigation and progression of oral diseases that can manifest into other systemic conditions. These associations encourage the exploration of oral dysbiosis leading to the pathogenesis of cancers. In this study, oral rinse was used to characterize the oral microbiome fluctuation associated with oral cavity cancer (OCC) and oropharyngeal cancers (OPC). The study cohort consists of normal healthy controls (n = 10, between 20 and 30 years of age; n = 10, above 50 years of age), high-risk individuals (n = 11, above 50 years of age with bad oral hygiene and/or oral diseases) and OCC and OPC patients (n = 31, HPV-positive; n = 21, HPV-negative). Oral rinse samples were analyzed using 16S rRNA gene amplicon sequencing on the MiSeq platform. Kruskal–Wallis rank test was used to identify genera associated with OCC and OPC. A logistic regression analysis was carried out to determine the performance of these genera as a biomarker panel to predict OCC and OPC. In addition, a two-fold cross-validation with a bootstrap procedure was carried out in R to investigate how well the panel would perform in an emulated clinical scenario. Our data indicate that the oral microbiome is able to predict the presence of OCC and OPC with sensitivity and specificity of 100 and 90%, respectively. With further validation, the panel could potentially be implemented into clinical diagnostic and prognostic workflows for OCC and OPC.
- Published
- 2018
158. The prognostic role of circulating tumor cells (CTCs) in lung cancer
- Author
-
Kapeleris, Joanna, Kulasinghe, Arutha, Ebrahimi Warkiani, Majid, Vela, Ian, Kenny, Lizbeth, O'Byrne, Ken, Punyadeera, Chamindie, Kapeleris, Joanna, Kulasinghe, Arutha, Ebrahimi Warkiani, Majid, Vela, Ian, Kenny, Lizbeth, O'Byrne, Ken, and Punyadeera, Chamindie
- Abstract
Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mortality globally. Currently, diagnosis of lung cancer involves a combination of imaging and invasive biopsies to confirm histopathology. Non-invasive diagnostic techniques under investigation include “liquid biopsies” through a simple blood draw to develop predictive and prognostic biomarkers. A better understanding of circulating tumor cell (CTC) dissemination mechanisms offers promising potential for the development of techniques to assist in the diagnosis of lung cancer. Enumeration and characterization of CTCs has the potential to act as a prognostic biomarker and to identify novel drug targets for a precision medicine approach to lung cancer care. This review will focus on the current status of CTCs and their potential diagnostic and prognostic utility in this setting.
- Published
- 2018
159. The use of microfluidic technology for cancer applications and liquid biopsy
- Author
-
Kulasinghe, Arutha, Wu, Hanjie, Punyadeera, Chamindie, Ebrahimi Warkiani, Majid, Kulasinghe, Arutha, Wu, Hanjie, Punyadeera, Chamindie, and Ebrahimi Warkiani, Majid
- Abstract
There is growing awareness for the need of early diagnostic tools to aid in point-of-care testing in cancer. Tumor biopsy remains the conventional means in which to sample a tumor and often presents with challenges and associated risks. Therefore, alternative sources of tumor biomarkers is needed. Liquid biopsy has gained attention due to its non-invasive sampling of tumor tissue and ability to serially assess disease via a simple blood draw over the course of treatment. Among the leading technologies developing liquid biopsy solutions, microfluidics has recently come to the fore. Microfluidic platforms offer cellular separation and analysis platforms that allow for high throughout, high sensitivity and specificity, low sample volumes and reagent costs and precise liquid controlling capabilities. These characteristics make microfluidic technology a promising tool in separating and analyzing circulating tumor biomarkers for diagnosis, prognosis and monitoring. In this review, the characteristics of three kinds of circulating tumor markers will be described in the context of cancer, circulating tumor cells (CTCs), exosomes, and circulating tumor DNA (ctDNA). The review will focus on how the introduction of microfluidic technologies has improved the separation and analysis of these circulating tumor markers.
- Published
- 2018
160. A pilot study to non-invasively track PIK3CA mutation in head and neck cancer
- Author
-
Schmidt, Henri, Kulasinghe, Arutha, Allcock, Richard, Tan, Lit Yeen, Mokany, Elisa, Kenny, Lizbeth, Punyadeera, Chamindie, Schmidt, Henri, Kulasinghe, Arutha, Allcock, Richard, Tan, Lit Yeen, Mokany, Elisa, Kenny, Lizbeth, and Punyadeera, Chamindie
- Abstract
Background: PIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in HNSCC progression and PIK3CA mutations may serve as predictive biomarkers for therapy selection. Circulating tumour DNA (ctDNA) derived from necrotic and apoptotic tumour cells are thought to harbour tumour-specific genetic alterations. As such, the detection of PIK3CA alterations detected by ctDNA holds promise as a potential biomarker in HNSCC. Methods: Blood samples from treatment naïve HNSCC patients (n = 29) were interrogated for a commonly mutated PIK3CA hotspot mutation using low cost allele-specific Plex-PCRTM technology. Results: In this pilot, cross sectional study, PIK3CA E545K mutation was detected in the plasma samples of 9/29 HNSCC patients using the Plex-PCRTM technology. Conclusion: The results of this pilot study support the notion of using allele-specific technologies for cost-effective testing of ctDNA, and further assert the potential utility of ctDNA in HNSCC.
- Published
- 2018
161. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer
- Author
-
Kulasinghe, Arutha, Kapeleris, Joanna, Kimberley, Rebecca, Mattarollo, Stephen, Thompson, Rik, Thiery, Jean-Paul, Kenny, Lizbeth, O'Byrne, Ken, Punyadeera, Chamindie, Kulasinghe, Arutha, Kapeleris, Joanna, Kimberley, Rebecca, Mattarollo, Stephen, Thompson, Rik, Thiery, Jean-Paul, Kenny, Lizbeth, O'Byrne, Ken, and Punyadeera, Chamindie
- Abstract
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, tumors change dynamically in response to therapy, and there remains a need for a more representative biomarker that can be assayed over the course of treatment. Circulating tumor cells (CTCs) may provide clinically important and comprehensive tumoral information that is predictive of treatment response and outcome. Blood samples were processed for CTCs from 56 patients using the ClearCell FX system. Captured cells were phenotyped for CTC clusters and markers for immunotherapy (PD‐L1) CTC chromosomal architecture (ALK, EGFR). CTCs were isolated in 11/23 (47.8%) of head and neck cancer (HNC) patients and 17/33 (51.5%) of non‐small‐cell lung cancer (NSCLC) patients. CTCs were determined to be PD‐L1‐positive in 6/11 (54.4%) HNC and 11/17 (64.7%) NSCLC cases, respectively. 3D chromosomal DNA FISH for ALK and EGFR molecular targets showed better resolution than in 2D when imaging CTCs. HNC CTC‐positive patients had shorter progression‐free survival (PFS) (hazard ratio[HR]: 4.946; 95% confidence internal[CI]:1.571‐15.57; P = 0.0063), and PD‐L1‐positive CTCs were found to be significantly associated with worse outcome ([HR]:5.159; 95% [CI]:1.011‐26.33; P = 0.0485). In the advanced stage NSCLC patient cohort, PFS was not found to be associated with CTCs prior to therapy ([HR]:2.246; 95% [CI]:0.9565‐5.273; P = 0.0632), nor the presence of PD‐L1 expression ([HR]:1.646; 95% [CI]:0.5128‐5.283; P = 0.4023). This study demonstrated that CTCs are predictive of poorer outcomes in HNC and provides distinct and separate utility for CTCs in HNC and NSCLC, which may be more representative of the disease burden and overall survival than the parameters used to measure them.
- Published
- 2018
162. Circulating tumor cells: The tumor trail left in the blood
- Author
-
Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Blick, Tony, Warkiani, Majid E., Vela, Ian, O'Byrne, Kenneth J., Thiery, Jean-Paul, Thompson, Erik, Nelson, Colleen, Punyadeera, Chamindie, Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Blick, Tony, Warkiani, Majid E., Vela, Ian, O'Byrne, Kenneth J., Thiery, Jean-Paul, Thompson, Erik, Nelson, Colleen, and Punyadeera, Chamindie
- Abstract
Background: Metastasis in HNC patients is reflected by measurable levels of circulating tumor cells (CTCs) in the peripheral blood of cancer patients. CTCs represent cancer cells from the primary and metastatic sites, thereby providing a comprehensive representation of the tumor burden of an individual patient. For patients without CTCs at presentation, the detection of CTCs in the blood and analysis of biomarkers within them provide an opportunity to identify patients "at risk" of developing overt metastasis, accelerating targeted treatment in addition to routing care with the clear aim of improving cure. Methods: Our study aimed to assess whether CTCs from the blood of HNC patients attending the Princess Alexandra Hospital and Royal Brisbane and Women's Hospital provided early cues of distant metastases (n=250). Results: With significant advances in CTC isolation technologies, we could demonstrate a higher CTC capture efficiency using epitope-independent platforms. By assessment of single and clustered CTCs, our data showed that HNC patients can be identified 4-6 months prior to developing clinical/radiographically evident metastasis. In these patients, a window for treatment escalation could become a possibility. In a proof-of-principle study, using novel culture formulations and hypoxic conditions (1-2% O2), we were able to demonstrate, for the first time, short-term patient-derived CTC cultures ex vivo from 7/18 HNC samples (4/7 HPV-positive, oropharyngeal) in a clinically relevant time period. Recent advancements have shown that PD-1 immune checkpoint therapies have durable responses in metastatic HNC patients that fail 1st- and 2nd-line therapy. Our preliminary data suggest PD-L1 is frequently expressed on HNC CTCs, and an immunoscore may be able to stratify patients likely to respond to immunotherapy. Conclusion: Expanding CTCs outside the patient's body allows for the recapitulation of the molecular diversity present within the t
- Published
- 2018
163. The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
- Author
-
Kapeleris, Joanna, primary, Kulasinghe, Arutha, additional, Warkiani, Majid E., additional, Vela, Ian, additional, Kenny, Liz, additional, O'Byrne, Kenneth, additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
164. The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
- Author
-
Kulasinghe, Arutha, primary, Wu, Hanjie, additional, Punyadeera, Chamindie, additional, and Warkiani, Majid, additional
- Published
- 2018
- Full Text
- View/download PDF
165. The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers
- Author
-
Lim, Yenkai, primary, Fukuma, Naoki, additional, Totsika, Makrina, additional, Kenny, Liz, additional, Morrison, Mark, additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
166. Abstract 5572: Circulating tumor cells: The tumor trail left in the blood
- Author
-
Kulasinghe, Arutha, primary, Perry, Chris, additional, Kenny, Liz, additional, Blick, Tony, additional, Warkiani, Majid, additional, Vela, Ian, additional, O'Byrne, Ken, additional, Thiery, Jean-Paul, additional, Thompson, Erik, additional, Nelson, Colleen, additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
167. Abstract 577: Oral microbiome biomarker panel to detect oral and oropharyngeal cancers in a clinical setting
- Author
-
Lim, Yenkai, primary, Fukuma, Naoki, additional, Totsika, Makrina, additional, Kenny, Liz, additional, Morrison, Mark, additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
168. Abstract 2207: High-risk human papillomavirus detection in head and neck cancers using saliva
- Author
-
Tang, Kai D, primary, Perry, Chris, additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
169. A Collective Route to Head and Neck Cancer Metastasis
- Author
-
Kulasinghe, Arutha, primary, Schmidt, Henri, additional, Perry, Chris, additional, Whitfield, Bernard, additional, Kenny, Liz, additional, Nelson, Colleen, additional, Warkiani, Majid E., additional, and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
170. A pilot study to investigate the feasibility of transporting saliva samples at room temperature with MAWI Cell Stabilization buffer
- Author
-
Lim, Yenkai, primary and Punyadeera, Chamindie, additional
- Published
- 2018
- Full Text
- View/download PDF
171. Development of Paper-Based Analytical Devices for Minimizing the Viscosity Effect in Human Saliva
- Author
-
Noiphung, Julaluk, primary, Nguyen, Michael P., additional, Punyadeera, Chamindie, additional, Wan, Yunxia, additional, Laiwattanapaisal, Wanida, additional, and Henry, Charles S., additional
- Published
- 2018
- Full Text
- View/download PDF
172. PD-L1 expressing circulating tumour cells in head and neck cancers
- Author
-
Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Warkiani, Majid E., Nelson, Colleen, Punyadeera, Chamindie, Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Warkiani, Majid E., Nelson, Colleen, and Punyadeera, Chamindie
- Abstract
Background: Blockade of the PD-1/PD-L1 immune checkpoint pathway is emerging as a promising immunotherapeutic approach for the management and treatment of head and neck cancer patients who do not respond to 1st/2nd line therapy. However, as checkpoint inhibitors are cost intensive, identifying patients who would most likely benefit from anti PD-L1 therapy is required. Developing a non-invasive technique would be of major benefit to the patient and to the health care system. Case presentation: We report the case of a 56 year old man affected by a supraglottic squamous cell carcinoma (SCC). A CT scan showed a 20 mm right jugulodigastric node and suspicious lung lesions. The lung lesion was biopsied and confirmed to be consistent with SCC. The patient was offered palliative chemotherapy. At the time of presentation, a blood sample was taken for circulating tumour cell (CTC) analysis. The dissemination of cancer was confirmed by the detection of CTCs in the peripheral blood of the patient, measured by the CellSearch System (Janssen Diagnostics). Using marker-independent, low-shear spiral microfluidic technology combined with immunocytochemistry, CTC clusters were found in this patient at the same time point, expressing PD-L1. Conclusion: This report highlights the potential use of CTCs to identify patients which might respond to anti PD-L1 therapy.
- Published
- 2017
173. Saliva: linking oral health with heart failure (Conference Abstract)
- Author
-
Zhang, Xi, Schulz, Benjamin, Walsh, Terry, Atherton, John, Kostner, Karam, Punyadeera, Chamindie, Zhang, Xi, Schulz, Benjamin, Walsh, Terry, Atherton, John, Kostner, Karam, and Punyadeera, Chamindie
- Abstract
The abstract is free to read at the publisher's website
- Published
- 2017
174. Within-day baseline variation in salivary biomarkers in healthy men
- Author
-
Idris, Firman Prathama, Wan, Yunxia, Zhang, Xi, Punyadeera, Chamindie, Idris, Firman Prathama, Wan, Yunxia, Zhang, Xi, and Punyadeera, Chamindie
- Abstract
Saliva is an easily accessible sample and offers practical and noninvasive biomarker solutions as an alternative to blood and urine-based diagnostics. Saliva contains a plethora of biomolecules such as nucleic acids, hormones, proteins, and electrolytes. On the other hand, little is known on the extent to which the biomolecules in saliva vary over time within a given person. This baseline information is crucial for future development of robust saliva-based diagnostics. We have collected unstimulated whole mouth saliva from 20 healthy young men at four times during the day, including before and after a meal. We measured the salivary cortisol, testosterone, C-reactive protein (CRP), stability of genomic DNA (gDNA) and DNA methylation levels of APC, P16INK4a, and PCQAP in these samples. We found that the salivary CRP, DNA methylation, and CD44 gDNA levels did not vary significantly across four time points (p>0.05) while the salivary cortisol and testosterone levels significantly varied from the morning collection to the afternoon collection (p<0.05). Furthermore, salivary cortisol levels were significantly affected by eating (p<0.05). Our study offers a within-person baseline temporal assessment of several clinically relevant biomolecules and diagnostics, and suggests that salivary cortisol and testosterone levels vary over time in a given day whereas CRP and DNA methylation of tumor suppressor genes and CD44 amplification are stable throughout the day. Future research and clinical applications of salivary biomarkers and diagnostics should take into consideration their temporal variations.
- Published
- 2017
175. Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients
- Author
-
Wan, Yunxia, Vagenas, Dimitrios, Salazar, Carolina, Kenny, Lizbeth, Perry, Chris, Calvopina, Diego, Punyadeera, Chamindie, Wan, Yunxia, Vagenas, Dimitrios, Salazar, Carolina, Kenny, Lizbeth, Perry, Chris, Calvopina, Diego, and Punyadeera, Chamindie
- Abstract
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of tumours that originate predominantly from the oral cavity, pharynx and larynx. Our aim was to determine whether salivary miRNA expression levels can diagnose these cancer subtypes. Saliva samples were collected from healthy controls (n=113, smoker and non-smokers), HPV-positive (n=54) and HPV-negative (n=47) HNSCC patients. The miRNA expression levels in saliva was quantified using qPCR. The potential of salivary miRNAs to discriminate these groups of patients was evaluated using multiple logistic regression with ROC analysis and a 10-fold cross-validation analysis. Salivary miRNA-9, -127, -134, -191, -222 and -455 were shown to discriminate a control group from a HPV-negative HNSCC patient group with a sensitivity of 60% and a specificity of 94%; whilst salivary miRNA-9,-134, -196b, -210, and -455 were the most parsimonious subset discriminating a control group from a HPV-positive HNSCC group, with a sensitivity of 65% and a specificity of 95%. Furthermore, miRNA-9, -134, -196b, -210 and -455 as a panel, was the most parsimonious subset to discriminate HPV-positive HNSCC patients from HPV-negative HNSCC patients. In addition, the expression levels of miRNA-9, -127, -196a, -196b, -210, -222 and -455 were significantly increased in the saliva collected from early stage HNSCC patients compared to controls. A future multi-centre confirmatory study is warranted to test the diagnostic performance of these salivary miRNA prior to clinical implementation.
- Published
- 2017
176. MicroRNAs in HPV associated cancers: small players with big consequences
- Author
-
Satapathy, Sandeep, Batra, Jyotsna, Jeet, Varinder, Thompson, Rik, Punyadeera, Chamindie, Satapathy, Sandeep, Batra, Jyotsna, Jeet, Varinder, Thompson, Rik, and Punyadeera, Chamindie
- Abstract
Introduction: MicroRNAs (miRs) are short (~20 nucleotides) non-coding ribonuecleic acids (ncRNAs) known to be involved in cellular processes such as proliferation, differentiation, immune response, pathogenicity and tumourigenesis, among many others. The regulatory mechanisms exerted by miRs have been implicated in many cancers, including Human Papillomavirus (HPV)-associated cancers. Areas covered: In this review, the authors discuss the involvement of miRs (−143, −375, −21, −200, −296 etc.) that have been shown to be dysregulated in HPV-associated cancers. This review also encompasses both intracellular and exosomal miRs, and their potential as diagnostic biomarkers in saliva and blood. The authors have also attempted to dissect the functional impact of miRs on cellular processes such as changes in cellular polarity, loss of apoptosis and tumour suppression, and unchecked and uncontrolled cell cycle regulation, all of which ultimately lead to aberrant cellular proliferation. Expert commentary: Identification of dysregulated miRs in HPV-associated cancers opens up new opportunities to develop diagnostic, therapeutic and prognostic biomarkers. Studies on global expression patterns of miRs dysregulated in HPV-associated cancers can be instrumental in developing broader therapeutic strategies. Therapies like anti-miR, miR-replacement and those based on alternative natural products targeting miRs, need to be improved and better synchronized to be cost-effective and have better treatment outcomes.
- Published
- 2017
177. Identification and validation of a salivary protein panel to detect heart failure early
- Author
-
Zhang, Xi, Walsh, Terry, Atherton, John, Kostner, Karam, Schulz, Benjamin, Punyadeera, Chamindie, Zhang, Xi, Walsh, Terry, Atherton, John, Kostner, Karam, Schulz, Benjamin, and Punyadeera, Chamindie
- Abstract
Background: Over 26 million people suffer from heart failure (HF) globally. Current diagnosis of HF relies on clinical evaluation, blood assays and imaging techniques. Our aim is to develop a diagnostic assay to detect HF in at risk individuals within the community using human saliva as a medium, potentially leading to a simple, safe early warning system. Methods: Saliva samples were collected from healthy controls (n=36) and HF patients (n=75). Salivary proteome profiles were analysed by Sequential Window Acquisition of All Theoretical fragment ion spectra – Mass Spectrometry (SWATH-MS). A total of 738 proteins were quantified and 177 proteins demonstrated significant differences between HF patients and healthy controls. Candidate biomarkers were chosen based on their abundance and difference between the two cohorts. A multi-protein panel was developed using logistic regression analysis. The diagnostic performance of the multi-protein panel was assessed using receiver operative characteristic curves. The candidate proteins were further confirmed, using western blot analysis, and validated technically, using an independent biological cohort. Results: A group of six proteins were chosen in the discovery phase as potential candidates based on their differences in the abundance between the two cohorts. During the validation phase, two of the proteins were not detected with western blotting and as such were removed. The final panel consists of four proteins with sensitivity of 83.3%, specificity of 62.5% with an area under ROC curve of 0.78 in discriminating healthy controls from NYHA class I/II HF patients, and was validated in a second independent cohort study. Conclusion: Analysis of salivary proteome using SWATH-MS revealed novel HF-specific protein candidates yielding high diagnostic performance. A multi-centre longitudinal clinical trial will be the next step before clinical implementation of this panel.
- Published
- 2017
178. Oral microbiome: A new biomarker reservoir for oral and oropharyngeal cancers
- Author
-
Lim, Yen Kai, Totsika, Makrina, Morrison, Mark, Punyadeera, Chamindie, Lim, Yen Kai, Totsika, Makrina, Morrison, Mark, and Punyadeera, Chamindie
- Abstract
Current biomarkers (DNA, RNA and protein) for oral cavity and oropharyngeal cancers demonstrate biological variations between individuals, rendering them impractical for clinical translation. Whilst these biomarkers originate from the host, there is not much information in the literature about the influence of oral microbiota on cancer pathogenesis, especially in oral cancers. Oral microbiotas are known to participate in disease initiation and progression not only limited to the oral cavity, but also at other distant sites. Due to the close proximity of oral microbiota and oral cavity and oropharyngeal tumours, abundance changes in oral microbiota may provide useful information on tumourigenesis. This review aims to highlight information on the role of oral microbiota in oral cavity and oropharyngeal cancers. An in-depth analysis into the oral microbiota may provide a new avenue to diagnose and treat these patients.
- Published
- 2017
179. The overexpression of salivary cytokeratins as potential diagnostic biomarkers in head and neck squamous cell carcinomas
- Author
-
Tang, Kai, Kenny, Lizbeth, Perry, Chris, Frazer, Ian, Punyadeera, Chamindie, Tang, Kai, Kenny, Lizbeth, Perry, Chris, Frazer, Ian, and Punyadeera, Chamindie
- Abstract
Background: Cytokeratin (CK) intermediate filaments are demonstrated to have enormous potential in regulating cellular motility and cancer progression. There are more than 20 divergent CKs that have been identified, of which CK 8, 17, 18 and 19 are reported to be elevated in the tumour biopsies of head and neck cancer squamous cell carcinoma (HNSCC) patients. However, CK expression profiles in the saliva of HNSCC patients have not been investigated. We aim to investigate the mRNA expression profiles of CKs in saliva collected from healthy controls, HPV-negative and -positive HNSCC patients. Methods: Oral rinse samples were collected from 42 cancer-free healthy controls (age-matched) and patients who have been diagnosed with HPV-negative (n = 20) and -positive (n = 48) HNSCC. Results: Here, we report that the mRNA expression profiles of CKs differed in saliva collected from healthy controls and HNSCC patients. The mRNA expression levels of CK 8 and 18 were significantly elevated in saliva collected from HPV-negative HNSCC patients; whilst, CK 17 and 19 were expressed at a higher mRNA level in saliva collected from HPV-positive HNSCC patients compared to healthy controls. Importantly, receiver operating characteristic (ROC) analysis showed salivary CK 8 and 18 to have superior sensitivity and specificity in discriminating the HPV-negative HNSCC patients from healthy controls (80% and 86%) as well as between HPV-negative and -positive HNSCC patients (75% and 81%). Conclusion: In summary, we have demonstrated that an aberrant expression of salivary CKs may serve as a potential non-invasive diagnostic biomarker in HNSCC.
- Published
- 2017
180. PD-L1 expressing circulating tumour cells in head and neck cancers
- Author
-
Kulasinghe, Arutha Jeevana, Perry, Chris, Kenny, Lizbeth, Ebrahimi Warkiani, Majid, Nelson, Colleen, Punyadeera, Chamindie, Kulasinghe, Arutha Jeevana, Perry, Chris, Kenny, Lizbeth, Ebrahimi Warkiani, Majid, Nelson, Colleen, and Punyadeera, Chamindie
- Abstract
Background Blockade of the PD-1/PD-L1 immune checkpoint pathway is emerging as a promising immunotherapeutic approach for the management and treatment of head and neck cancer patients who do not respond to 1st/2nd line therapy. However, as checkpoint inhibitors are cost intensive, identifying patients who would most likely benefit from anti PD-L1 therapy is required. Developing a non-invasive technique would be of major benefit to the patient and to the health care system. Case presentation We report the case of a 56 year old man affected by a supraglottic squamous cell carcinoma (SCC). A CT scan showed a 20 mm right jugulodigastric node and suspicious lung lesions. The lung lesion was biopsied and confirmed to be consistent with SCC. The patient was offered palliative chemotherapy. At the time of presentation, a blood sample was taken for circulating tumour cell (CTC) analysis. The dissemination of cancer was confirmed by the detection of CTCs in the peripheral blood of the patient, measured by the CellSearch System (Janssen Diagnostics). Using marker-independent, low-shear spiral microfluidic technology combined with immunocytochemistry, CTC clusters were found in this patient at the same time point, expressing PD-L1. Conclusion This report highlights the potential use of CTCs to identify patients which might respond to anti PD-L1 therapy.
- Published
- 2017
181. A pilot study into the association between oral health status and human papillomavirus - 16 infection
- Author
-
Sun, Charles Xiaohang, Bennett, Nigel, Tran, Peter, Tang, Kai, Lim, Yen Kai, Frazer, Ian, Samaranayake, Lakshman, Punyadeera, Chamindie, Sun, Charles Xiaohang, Bennett, Nigel, Tran, Peter, Tang, Kai, Lim, Yen Kai, Frazer, Ian, Samaranayake, Lakshman, and Punyadeera, Chamindie
- Abstract
Background Over the next 20 years, oropharyngeal cancers (OPC) will represent the majority of head and neck cancers (HNCs) in the United States. It is estimated that human papillomavirus (HPV) may account for as much as 70% to 80% of OPCs in North America and in certain parts of Europe. It is hence crucial to understand the disease risk factors and natural history of oral HPV infections. We hypothesized that poor oral health (by measures such as poor oral hygiene and periodontal disease) leads to a higher degree of oral HPV-16 infections within a patient cohort from a dental school clinic. This study aims to test this hypothesis and gauge possible disease associations before larger scale studies. Subjects and Methods 223 participants were recruited in this study from the University of Queensland Dental School clinic. Clinical oral health parameters (such as oral hygiene measures and periodontal disease measurements) have been examined and determined by dental professionals. We have collected oral rinse samples from these volunteers. Results 10 (4.5%) out of 223 participants were found to have HPV-16 DNA in their oral rinse samples using NB2 endpoint PCR and Sanger sequencing. Within the HPV-16 DNA positive subjects, 7 (70%) and 3 (30%) were associated with poor oral hygiene and periodontal disease, respectively. Conclusion Our results show a trend towards a positive correlation between oral HPV-16 infection and poor clinical oral health status.
- Published
- 2017
182. Enrichment of circulating head and neck tumour cells using spiral microfluidic technology
- Author
-
Kulasinghe, Arutha Jeevana, Tran, Thao Huynh Phuoc, Blick, Tony, O'Byrne, Ken, Thompson, Rik, Ebrahimi Warkiani, Majid, Nelson, Colleen, Kenny, Lizbeth, Punyadeera, Chamindie, Kulasinghe, Arutha Jeevana, Tran, Thao Huynh Phuoc, Blick, Tony, O'Byrne, Ken, Thompson, Rik, Ebrahimi Warkiani, Majid, Nelson, Colleen, Kenny, Lizbeth, and Punyadeera, Chamindie
- Abstract
Whilst locoregional control of head and neck cancers (HNCs) has improved over the last four decades, long-term survival has remained largely unchanged. A possible reason for this is that the rate of distant metastasis has not changed. Such disseminated disease is reflected in measurable levels of cancer cells in the blood of HNC patients, referred to as circulating tumour cells (CTCs). Numerous marker-independent techniques have been developed for CTC isolation and detection. Recently, microfluidics-based platforms have come to the fore to avoid molecular bias. In this pilot, proof of concept study, we evaluated the use of the spiral microfluidic chip for CTC enrichment and subsequent detection in HNC patients. CTCs were detected in 13/24 (54%) HNC patients, representing both early to late stages of disease. Importantly, in 7/13 CTC-positive patients, CTC clusters were observed. This is the first study to use spiral microfluidics technology for CTC enrichment in HNC.
- Published
- 2017
183. Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients
- Author
-
Wan, Yunxia, primary, Vagenas, Dimitrios, additional, Salazar, Carolina, additional, Kenny, Liz, additional, Perry, Chris, additional, Calvopiña, Diego, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
184. The saliva microbiome profiles are minimally affected by collection method or DNA extraction protocols
- Author
-
Lim, Yenkai, primary, Totsika, Makrina, additional, Morrison, Mark, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
185. The overexpression of salivary cytokeratins as potential diagnostic biomarkers in head and neck squamous cell carcinomas
- Author
-
Tang, Kai Dun, primary, Kenny, Liz, additional, Perry, Chris, additional, Frazer, Ian, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
186. PD-L1 expressing circulating tumour cells in head and neck cancers
- Author
-
Kulasinghe, Arutha, primary, Perry, Chris, additional, Kenny, Liz, additional, Warkiani, Majid E., additional, Nelson, Colleen, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
187. A Pilot Study into the Association between Oral Health Status and Human Papillomavirus—16 Infection
- Author
-
Sun, Charles, primary, Bennett, Nigel, additional, Tran, Peter, additional, Tang, Kai, additional, Lim, Yenkai, additional, Frazer, Ian, additional, Samaranayake, Lakshman, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
188. Enrichment of circulating head and neck tumour cells using spiral microfluidic technology
- Author
-
Kulasinghe, Arutha, primary, Tran, Thao Huynh Phuoc, additional, Blick, Tony, additional, O’Byrne, Ken, additional, Thompson, Erik W., additional, Warkiani, Majid E., additional, Nelson, Colleen, additional, Kenny, Liz, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
189. Within-Day Baseline Variation in Salivary Biomarkers in Healthy Men
- Author
-
Idris, Firman Prathama, primary, Wan, Yunxia, additional, Zhang, Xi, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
190. Oral Microbiome: A New Biomarker Reservoir for Oral and Oropharyngeal Cancers
- Author
-
Lim, Yenkai, primary, Totsika, Makrina, additional, Morrison, Mark, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
191. Identification and Validation of a Salivary Protein Panel to Detect Heart Failure Early
- Author
-
Zhang, Xi, primary, Walsh, Terry, additional, Atherton, John J, additional, Kostner, Karam, additional, Schulz, Benjamin, additional, and Punyadeera, Chamindie, additional
- Published
- 2017
- Full Text
- View/download PDF
192. High‐risk human papillomavirus detection in oropharyngeal cancers: Comparison of saliva sampling methods.
- Author
-
Tang, Kai Dun, Punyadeera, Chamindie, Kenny, Liz, and Frazer, Ian H.
- Subjects
SALIVA ,SAMPLING methods ,CANCER - Abstract
Background: Accumulating evidence has suggested the utility of salivary oral rinse as a diagnostic fluid to detect oral human papillomavirus (HPV) DNA, but there are many methods for collecting saliva. Methods: Salivary oral rinse and unstimulated whole mouth saliva samples were collected from 45 oropharyngeal cancer (OPC) patients. Results: We show a positive correlation of HPV‐16 E2 (r = 0.95, P < 0.0001) and E6/7 (r = 0.93, P < 0.0001) relative copy number as well as HPV genotypes in both sample methods. There was a significant correlation between the two sample methods in the ratio of HPV16 E2 to E6/7 DNA (r = 0.46, P < 0.01). Consistent with previous studies, a mixed HPV‐16 form (episomal and integrated) was commonly found in both saliva and tumor samples. Conclusion: Detection of HPV in saliva samples collected by either method yielded comparable results, and showed good sensitivity for detection of HPV derived from OPC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
193. Surveillance of human papillomavirus through salivary diagnostics - A roadmap to early detection of oropharyngeal cancer men
- Author
-
Wijesekera, Akila, Weeramange, Chameera Ekanayake, Vasani, Sarju, Kenny, Liz, Knowland, Emma, Seneviratne, Jayampath, and Punyadeera, Chamindie
- Abstract
Human papillomavirus (HPV) is the most common sexually transmitted disease. Certain strains have the potential to cause malignancy in multiple anatomical sites if not cleared by the immune system. In most infected people, HPV is cleared within two years. However, HPV may persist in susceptible individuals with certain risk factors, eventually leading to malignancy. New evidence suggests that over 75% of all oropharyngeal cancers (OPC) are directly attributable to HPV. It is estimated that prophylactic HPV vaccination alone may take at least 25 years to have a significant impact on reducing the incidence of OPC. The temporal link between detection of oral HPV, persistence of the infection and the subsequent development of OPC have been well established. Moreover, men have threefold higher risk than women for acquiring HPV-OPC. This comprehensive review focuses on OPC development in men, highlighting the risk factors associated with malignant transformation of HPV-OPC. Current evidence is insufficient to determine whether early identification of at-risk demographics, screening, and prompt diagnosis result in improved outcomes. Hitherto, the effectiveness of an oral HPV screening program in this regard has not been investigated. Nevertheless, the potential to emulate the success of the cervical screening program remains a very real possibility.
- Published
- 2024
- Full Text
- View/download PDF
194. Circulating tumor cells: Isolation, expansion, characterization and translation to clinic
- Author
-
Ray, P C, Kulasinghe, Arutha Jeevana, Schmidt, Henri, Punyadeera, Chamindie, Ray, P C, Kulasinghe, Arutha Jeevana, Schmidt, Henri, and Punyadeera, Chamindie
- Abstract
Circulating tumor cells (CTCs) are the seeds for cancer metastases development, which is responsible for >90% of cancer-related deaths. Accurate quantification of CTCs in human fluids could be an invaluable tool for understanding cancer prognosis, delivering personalized medicine to prevent metastasis and finding cancer therapy effectiveness. Although CTCs were first discovered more than 200 years ago, until now it has been a nightmare for clinical practitioners to capture and diagnose CTCs in clinical settings. Our society needs rapid, sensitive, and reliable assays to identify the CTCs from blood in order to help save millions of lives. Due to the phenotypic EMT transition, CTCs are undetected for more than one-third of metastatic breast cancer patients in clinics. To tackle the above challenges, the first volume in “Circulating Tumor Cells (CTCs): Detection Methods, Health Impact and Emerging Clinical Challenges discusses recent developments of different technologies, which have the capability to target and elucidate the phenotype heterogenity of CTCS. It contains seven chapters written by world leaders in this area, covering basic science to possible device design which can have beneficial applications in society. This book is unique in its design and content, providing an in-depth analysis to elucidate biological mechanisms of cancer disease progression, CTC detection challenges, possible health effects and the latest research on evolving technologies which have the capability to tackle the above challenges. It describes the broad range of coverage on understanding CTCs biology from early predictors of the metastatic spread of cancer, new promising technology for CTC separation and detection in clinical environment and monitoring therapy efficacy via finding the heterogeneous nature of CTCs. (Imprint: Nova Biomedical)
- Published
- 2016
195. Impact of label-free technologies in head and neck cancer circulating tumour cells
- Author
-
Kulasinghe, Arutha Jeevana, Kenny, Lizbeth, Perry, Chris, Thiery, Jean-Paul, Jovanovic, Lidija, Vela, Ian, Nelson, Colleen, Punyadeera, Chamindie, Kulasinghe, Arutha Jeevana, Kenny, Lizbeth, Perry, Chris, Thiery, Jean-Paul, Jovanovic, Lidija, Vela, Ian, Nelson, Colleen, and Punyadeera, Chamindie
- Abstract
Background The ability to identify high risk head and neck cancer (HNC) patients with disseminated disease prior to presenting with clinically detectable metastases holds remarkable potential. A fraction of circulating tumour cells (CTCs) are invasive cancer cells which mediate metastasis by intravasation, survival and extravasation from the blood stream to metastatic sites. CTCs have been cleared by the FDA for use as surrogate markers of overall survival and progression free survival for breast, prostate and colorectal cancers using the CellSearch® system. However, the clinical significance of CTCs in head and neck cancer patients has yet to be determined. There has been a significant shift in CTC enrichment platforms, away from exclusively single marker selection, to epitope-independent systems. Methods The aim of this study was to screen advanced stage HNC patients by the CellSearch® platform and utilise two other epitope-independent approaches, ScreenCell® (microfiltration device) and RosetteSep™ (negative enrichment), to determine how a shift to such methodologies would enable CTC enrichment and detection. Results In advanced stage HNC patients, single CTCs were detected in 8/43 (18.6%) on CellSearch®, 13/28 (46.4%) on ScreenCell® and 16/25 (64.0%) by RosetteSep™ (the latter could also detect CTC clusters). Notably, in patients with suspicious lung nodules, too small to biopsy, CTCs were found upon presentation. Moreover, CTCs were readily detected in advanced stage HNC patients. Conclusion The epitope-independent platforms detected higher CTC numbers and clusters. Further studies are needed to ascertain whether CTCs can be used as independent prognostic markers for HNCs.
- Published
- 2016
196. Short term ex-vivo expansion of circulating head and neck tumour cells
- Author
-
Kulasinghe, Arutha Jeevana, Perry, Chris, Ebrahimi Warkiani, Majid, Blick, Tony, Davies, Anthony, O'Byrne, Ken, Thompson, Rik, Nelson, Colleen, Vela, Ian, Punyadeera, Chamindie, Kulasinghe, Arutha Jeevana, Perry, Chris, Ebrahimi Warkiani, Majid, Blick, Tony, Davies, Anthony, O'Byrne, Ken, Thompson, Rik, Nelson, Colleen, Vela, Ian, and Punyadeera, Chamindie
- Abstract
Minimally invasive techniques are required for the identification of head and neck cancer (HNC) patients who are at an increased risk of metastasis, or are not responding to therapy. An approach utilised in other solid cancers is the identification and enumeration of circulating tumour cells (CTCs) in the peripheral blood of patients. Low numbers of CTCs has been a limiting factor in the HNC field to date. Here we present a methodology to expand HNC patient derived CTCs ex-vivo. As a proof of principle study, 25 advanced stage HNC patient bloods were enriched for circulating tumour cells through negative selection and cultured in 2D and 3D culture environments under hypoxic conditions (2% O2, 5% CO2). CTCs were detected in 14/25 (56%) of patients (ranging from 1–15 CTCs/5 mL blood). Short term CTC cultures were successfully generated in 7/25 advanced stage HNC patients (5/7 of these cultures were from HPV+ patients). Blood samples from which CTC culture was successful had higher CTC counts (p = 0.0002), and were predominantly from HPV+ patients (p = 0.007). This is, to our knowledge, the first pilot study to culture HNC CTCs ex-vivo. Further studies are warranted to determine the use of short term expansion in HNC and the role of HPV in promoting culture success.
- Published
- 2016
197. Salivary epigenetic biomarkers in head and neck squamous cell carcinomas
- Author
-
Lim, Yen-Kai, Sun, Charles Xiaohang, Tran, Peter, Punyadeera, Chamindie, Lim, Yen-Kai, Sun, Charles Xiaohang, Tran, Peter, and Punyadeera, Chamindie
- Abstract
The early detection of head and neck squamous cell carcinoma (HNSCC) continues to be a challenge to the clinician. Saliva as a diagnostic medium carries significant advantages including its close proximity to the region of interest, ease of collection and noninvasive nature. While the identification of biomarkers continues to carry significant diagnostic and prognostic utility in HNSCC, epigenetic alterations present a novel opportunity to serve this purpose. With the developments of novel and innovative technologies, epigenetic alterations are now emerging as attractive candidates in HNSCC. As such, this review will focus on two commonly aberrant epigenetic alterations: DNA methylation and microRNA expression in HNSCC and their potential clinical utility. Identification and validation of these salivary epigenetic biomarkers would not only enable early diagnosis but will also facilitate in the clinical management.
- Published
- 2016
198. A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16INK4a expression in head and neck squamous cell carcinoma patients
- Author
-
Chai, Ryan, Lim, Yen-Kai, Frazer, Ian, Wan, Yunxia, Perry, Chris, Jones, Lee, Lambie, Duncan, Punyadeera, Chamindie, Chai, Ryan, Lim, Yen-Kai, Frazer, Ian, Wan, Yunxia, Perry, Chris, Jones, Lee, Lambie, Duncan, and Punyadeera, Chamindie
- Abstract
BackgroundHuman papilloma virus-16 (HPV-16) infection is a major risk factor for a subset of head and neck squamous cell carcinoma (HNSCC), in particular oropharyngeal squamous cell carcinoma (OPSCC). Current techniques for assessing the HPV-16 status in HNSCC include the detection of HPV-16 DNA and p16INK4a expression in tumor tissues. When tumors originate from hidden anatomical sites, this method can be challenging. A non-invasive and cost-effective alternative to biopsy is therefore desirable for HPV-16 detection especially within a community setting to screen at-risk individuals.Of 42 patients with p16INK4a-positive tumours, 39 (sensitivity = 92.9 %, PPV = 100 % and NPV = 93 %) had oral rinse samples with detectable HPV-16 DNA, using end-point and quantitative PCR. No HPV-16 DNA was detected in oral rinse samples from 40 patients with p16INK4a negative tumours, yielding a test specificity of 100 %. For patients with p16INK4a positive tumours, HPV-16 mRNA was detected using end-point reverse transcription PCR (RT-PCR) in 24/40 (sensitivity = 60 %, PPV = 100 % and NPV = 71 %), and using quantitative RT-PCR in 22/40 (sensitivity = 55 %, PPV = 100 % and NPV = 69 %). No HPV-16 mRNA was detected in oral
- Published
- 2016
199. A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva
- Author
-
Zhang, Xi, Wan, Yunxia, Chata, Roberto, Brazzale, Anthony, Atherton, John, Kostner, Karam, Dimeski, Goce, Punyadeera, Chamindie, Zhang, Xi, Wan, Yunxia, Chata, Roberto, Brazzale, Anthony, Atherton, John, Kostner, Karam, Dimeski, Goce, and Punyadeera, Chamindie
- Abstract
Aim - Heart failure (HF) affects millions of older individuals in both developed and low/middle-income countries. Serum galectin-3 levels have been shown to have prognostic value. However, its use as a diagnostic biomarker has not been explored. The aim was to establish a saliva galectin-3 reference range and to demonstrate the potential diagnostic utility of salivary and serum galectin-3 levels in assessing HF. Methods - Blood and saliva samples were collected from age-matched healthy controls (n=51) and patients with HF (n=63). Customised immunoassays were developed to quantify salivary galectin-3 levels. The diagnostic performances of these assays were evaluated by receiver operator characteristic (ROC) curves analysis. Results - The galectin-3 concentrations were significantly elevated in saliva and serum samples of patients with HF compared with controls (p<0.001 and p<0.0001, respectively). Using ROC curve analysis, both serum and salivary galectin-3 gave area under the curve (AUC)=0.86 and AUC=0.73, respectively. There was also a significant correlation (r=0.4, p<0.01) between serum and salivary galectin-3 levels. Conclusions - For the first time, we have quantified galectin-3 levels in human saliva and have demonstrated potential clinical utility in diagnosing HF. Further, larger multicentre clinical trials are needed before salivary galectin-3 levels can be implemented in a clinical setting.
- Published
- 2016
200. Variation of human salivary O-glycome
- Author
-
Kozak, Radoslaw, Urbanowicz, Paulina, Punyadeera, Chamindie, Reiding, Karli, Jansen, Bas, Royal, Louise, Spencer, Daniel, Fernandes, Daryl, Wuhrer, Manfred, Kozak, Radoslaw, Urbanowicz, Paulina, Punyadeera, Chamindie, Reiding, Karli, Jansen, Bas, Royal, Louise, Spencer, Daniel, Fernandes, Daryl, and Wuhrer, Manfred
- Abstract
The study of saliva O-glycosylation is receiving increasing attention due to the potential of glycans for disease biomarkers, but also due to easy access and non-invasive collection of saliva as biological fluid. Saliva is rich in glycoproteins which are secreted from the bloodstream or produced by salivary glands. Mucins, which are highly O-glycosylated proteins, are particularly abundant in human saliva. Their glycosylation is associated with blood group and secretor status, and represents a reservoir of potential disease biomarkers. This study aims to analyse and compare O-glycans released from whole human mouth saliva collected 3 times a day from a healthy individual over a 5 days period. O-linked glycans were released by hydrazinolysis, labelled with procainamide and analysed by ultra-high performance liquid chromatography with fluorescence detection (UHPLC-FLR) coupled to electrospray ionization mass spectrometry (ESI-MS/MS). The sample preparation method showed excellent reproducibility and can therefore be used for biomarker discovery. Our data demonstrates that the O-glycosylation in human saliva changes significantly during the day. These changes may be related to changes in the salivary concentrations of specific proteins.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.